Evidence map›Paper›PMID 39185643›Full record

ArticleCurrent pharmaceutical biotechnology2025

Formulation, Characterization, and Potential Therapeutic Implications of Encapsulated Recombinant Alpha-luffin in Niosomes.

Hajar Abedi Joni, Fariba Esmaeili, Behnaz Landi, Elham Bayat, Haleh Bakhshandeh, Yeganeh Talebkhan, Farzaneh Barkhordari, Somayeh Sadeghi, Leila Nematollahi, Babak Negahdari

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hajar Abedi JoniDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Fariba EsmaeiliDepartment of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Behnaz LandiBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Elham BayatBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Haleh BakhshandehDepartment of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran.
Yeganeh TalebkhanBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Farzaneh BarkhordariBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Somayeh SadeghiDepartment of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran.
Leila NematollahiBiotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Babak NegahdariDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8742-9138

Funding

Tehran University of Medical Sciences 99-1-148-47045
6 · The paper itself

Abstract

objectiveThe anticancer properties of recombinant α-luffin (LUF) are wellestablished. However, the cytotoxic effects of encapsulating LUF within niosomes on the SKBR3 breast cancer cell line have yet to be explored. Our study aimed to investigate whether this encapsulation strategy could improve cytotoxic effects.

methodsAlpha-luffin was expressed, purified, and refolded. Then, this protein was utilized to craft an optimal formulation, guided by experimental design. In this work, we have explored various physicochemical properties, including particle size, polydispersity index, zeta potential, morphology, entrapment efficiency, drug release and kinetics, storage stability, and FTIR spectroscopy. Additionally, we have assessed the cellular uptake and cytotoxic effect of the optimized niosome formulation on the SKBR3 breast cancer cell line.

resultsThe optimized niosome exhibited a mean diameter of 315±6.4 nm (DLS). Successful encapsulation of LUF into regularly shaped, spherical niosomes was achieved, with an encapsulation efficiency of 73.45±2.4%. Notably, Niosomal LUF (NLUF) exhibited significantly increased cytotoxicity against SKBR3 cells.

conclusionThese findings suggest that niosomes loaded with LUF hold promise as a potential treatment strategy for breast cancer.

Indexed as

Antineoplastic AgentsLiposomesBreast NeoplasmsCell Line, TumorCell SurvivalDrug CompoundingDrug LiberationFemaleHumansParticle SizeRecombinant ProteinsAntineoplastic AgentsLiposomesRecombinant Proteinsalphaluffin.drug deliveryNiosomerecombinant proteinresponse surface methodologyribosome-inactivating protein

Identifiers

PMID39185643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.